ACHV - Achieve Life Sciences Inc logo

Achieve Life Sciences Inc

ACHV

Achieve Life Sciences develops and commercializes cytisinicline, a treatment for nicotine dependence in North America and the UK. The drug targets nicotine receptors to alleviate withdrawal symptoms, aiming to help smokers quit effectively.

βš•οΈ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago β†’$0today

Score Overview

1 Year
Scoreβ€”
Net Growth-108.68%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Scoreβ€”
Net Growth-246.61%
Net Trend20%
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendNever
Revenue Consistencyβ€”
10 Years
Score
Net Growth-466.55%
Net Trend30%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
20 Years
Score1.5
Net Growth-384.22%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
30 Years
Score
Net Growth-67x
Net Trend37%
Net Income Consistency
Rev Growth-100.00%
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-17x
Net Trend39%
Net Income Consistency
Rev Growth-100.00%
Rev Trend32%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Achieve Life Sciences Inc has ranked, year by year

Measure
Fundamentals Window

Showing 20 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ACHV

2016: 98.6% Β· 2021: 99.7% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 8.09β€”
1 Year2025-09-30
$ 3.15156.83%
5 Years2021-09-30
$ 8.50-4.82%
10 Years2016-09-30
$ 1.12K-99.27%
20 Years2006-09-29
$ 185.72K-100.00%
30 Years1996-09-27
$ 772.2K-100.00%
All Time1995-10-13
$ 282.15K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 114M$ 187M
2025$ 0.00-$ 54M$ 36M
2024$ 0.00-$ 39M$ 34M
2023$ 0.00-$ 29M$ 15M
2022$ 0.00-$ 41M$ 24M
2021$ 0.00-$ 32M$ 43M
2020$ 0.00-$ 14M$ 35M
2019$ 0.00-$ 16M$ 16M
2018$ 0.00-$ 12M$ 14M
2017$ 0.00-$ 10M$ 5M
2016$ 5M-$ 20M$ 25M
2015$ 18M-$ 16M$ 55M
2014$ 27M-$ 26M$ 47M
2013$ 29M-$ 31M$ 39M
2012$ 20M-$ 21M$ 75M
2011$ 5M-$ 14M$ 64M
2010$ 13M-$ 12M$ 85M
2009$ 25M$ 5M$ 64M
2008$ 20M-$ 4M$ 13M
2007$ 20M-$ 13M$ 34M
2006$ 22M-$ 23M$ 58M
2005$ 8M-$ 21M$ 49M
2004$ 264M-$ 16M$ 20M
2003-$ 10M$ 19M
2002-$ 11M$ 16M
2001$ 8M$ 542.18K$ 15M
2000$ 408.41K-$ 2M$ 13M
1999$ 12M$ 400K$ 16M
1998$ 5M-$ 11M$ 17M
1997$ 18M$ 1M$ 5M
1996$ 16M$ 1M$ 7M
IPO1995$ 4M-$ 5M$ 5M
ACHV - Achieve Life Sciences Inc logo

Achieve Life Sciences Inc fundamental performance

Between 2005 and 2025, revenue declined from $ 8M to $ 0.00 and net income went from -$ 21M to -$ 54M. Revenue increased in 4 of those 20 years; net income in 8.

Across Achieve Life Sciences Inc's full reported history, from 1995 to 2025, revenue declined from $ 4M to $ 0.00 and net income went from -$ 5M to -$ 54M. Revenue increased in 32% of the years measured; net income in 39%.

Achieve Life Sciences Inc currently holds a 20-year HDB Score of 1.5 out of 10. How the HDB Score is calculated.

Membership

Continue ACHV’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies